Adverum Biotechnologies (NASDAQ:ADVM) (NASDAQ: ADVM) is a clinical-stage gene therapy company dedicated to developing next-generation treatments for ocular and rare diseases. Headquartered in Redwood City, California, Adverum leverages its proprietary adeno-associated virus (AAV) platform to deliver potentially one-time, durable therapies that address underlying genetic causes. The company’s research focuses on serious conditions with high unmet medical need, including retinal disorders and hemophilia A.
The company’s pipeline includes ADVM-022, an intravitreal AAV-based gene therapy candidate for the prevention and treatment of neovascular age-related macular degeneration (wet AMD), and ADVM-043, which targets diabetic macular edema. In addition, Adverum is advancing ADVM-269, a systemic AAV vector designed to express factor VIII for patients with severe hemophilia A. Each program is designed to reduce or eliminate the need for repeated hospital visits and chronic treatment regimens.
Originally founded as Avalanche Biotechnologies in 2014 and rebranded as Adverum Biotechnologies in 2015, the company completed its initial public offering on the Nasdaq in 2016. Under the leadership of President and CEO Roy Dunbar and Executive Chairman Glenn Rockman, Adverum has grown its scientific capabilities and manufacturing partnerships, including agreements to secure clinical- and commercial-scale AAV vector production.
Adverum operates with a global perspective, conducting clinical trials across North America and Europe and engaging with regulatory authorities to advance its programs. The company’s mission is to bring transformative gene therapies to patients worldwide, harnessing its expertise in vector design and delivery to develop potentially curative treatments for serious disorders.
